New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
16:10 EDTAERIAerie Pharmaceuticals reports Q4 GAAP EPS (62c), consensus (25c)
Included in the $10.3M net loss and the (62c) EPS are non-cash charges totaling $4.9M, of which $1.3M represents stock-based compensation expense included in operating expenses. With these non-cash items excluded, the adjusted operating expenses of $5.4M include adjusted research and development expenses of $3.0M and adjusted general and administrative expenses of $2.4M. In addition to the $1.3M stock-based compensation expense, the $4.9M in non-cash charges include a $2.7M extinguishment loss related to the conversion of the Company’s outstanding convertible promissory notes to common equity upon the closing of the IPO and $900,000 in accrued interest and amortization expense related to the Company’s notes that were converted to common equity upon the closing of the IPO.
News For AERI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
09:09 EDTAERIAerie Pharmaceuticals management to meet with Needham
Subscribe for More Information
November 11, 2014
16:06 EDTAERIAerie Pharmaceuticals reports Q3 EPS (54c), consensus (41c)
As of September 30, the company had cash, cash equivalents and investments of $171.1M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use